Information presented on this call is contained in the press release issued today and the company's Form 10-Q ... that this year. The application is supported by data from four well-controlled ...

Filed a key provisional patent application with the United States Patent and Trademark Office (USPTO) entitled "PSMA-Targeted PARP ... Strengthened the Company's balance sheet through the completion ...

Select FDA Patent Term Extension Application for Elahere (mirvetuximab soravtansine-gynx), Patent No. 8,557,966 FDA-2023-E-3231 Select FDA Patent Term Extension Application for Elahere (mirvetuximab ...

$ 259.50 1.13 0.44% ...

Financials are currently not available. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.